U.S. markets closed
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • Dow 30

    35,144.31
    +82.76 (+0.24%)
     
  • Nasdaq

    14,840.71
    +3.72 (+0.03%)
     
  • Russell 2000

    2,216.92
    +7.27 (+0.33%)
     
  • Crude Oil

    72.17
    +0.10 (+0.14%)
     
  • Gold

    1,798.00
    -3.80 (-0.21%)
     
  • Silver

    25.26
    +0.03 (+0.13%)
     
  • EUR/USD

    1.1809
    +0.0039 (+0.33%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3822
    +0.0068 (+0.49%)
     
  • USD/JPY

    110.3800
    -0.1300 (-0.12%)
     
  • BTC-USD

    37,958.67
    +3,545.86 (+10.30%)
     
  • CMC Crypto 200

    905.69
    -9.80 (-1.07%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

La Jolla Pharma's drug improves kidney function in mid-stage study

March 10 (Reuters) - La Jolla Pharmaceutical Co said its experimental drug to treat chronic kidney disease met the main goal of improving kidney function in a mid-stage study.

The company said a lower dose of the drug, codenamed GCS-100, showed an increase in the rate of blood filtering through the kidneys, compared with a placebo.